Immunology, Virology, Internal medicine, Acquired immunodeficiency syndrome and Virus are his primary areas of study. His Immunology research integrates issues from Cohort and Risk factor. Eric S. Daar combines subjects such as Incidence and Drug resistance with his study of Virology.
His biological study spans a wide range of topics, including Gastroenterology, Efavirenz, Viral load and Emtricitabine. His Acquired immunodeficiency syndrome research includes themes of Viral disease, Asymptomatic and Immunopathology. Eric S. Daar interconnects Epitope, Antibody and Ex vivo in the investigation of issues within Virus.
His primary scientific interests are in Internal medicine, Immunology, Virology, Acquired immunodeficiency syndrome and Viral load. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Efavirenz and Emtricitabine. Eric S. Daar has included themes like Tenofovir alafenamide, Abacavir, Reverse-transcriptase inhibitor, Abacavir/Lamivudine and Ritonavir in his Emtricitabine study.
His studies in Immunology integrate themes in fields like Cytotoxic T cell and Men who have sex with men. His work deals with themes such as Antibody and Drug resistance, which intersect with Virology. The various areas that Eric S. Daar examines in his Acquired immunodeficiency syndrome study include Viral disease, Psychological intervention, Substance abuse and Immunopathology.
Eric S. Daar focuses on Internal medicine, Randomized controlled trial, Emtricitabine, Men who have sex with men and Pre-exposure prophylaxis. His work carried out in the field of Internal medicine brings together such families of science as Abacavir, Acquired immunodeficiency syndrome, Antiretroviral therapy and Oncology. Within one scientific family, Eric S. Daar focuses on topics pertaining to Placebo under Acquired immunodeficiency syndrome, and may sometimes address concerns connected to Clinical trial.
His Randomized controlled trial study also includes fields such as
Eric S. Daar mainly investigates Internal medicine, Randomized controlled trial, Emtricitabine, Men who have sex with men and Pre-exposure prophylaxis. His work on Odds ratio, Phases of clinical research and Methotrexate as part of general Internal medicine research is often related to Brachial artery and Multicenter trial, thus linking different fields of science. His research in Randomized controlled trial intersects with topics in Causal inference, Estimator and External validity.
His Emtricitabine research is multidisciplinary, incorporating perspectives in Abacavir, Regimen, Darunavir, Reverse-transcriptase inhibitor and Ritonavir. His Men who have sex with men research is multidisciplinary, relying on both Logistic regression and Public health. The Pre-exposure prophylaxis study combines topics in areas such as Clinical endpoint, Dosing, Statistical significance and Confidence interval.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
Susan J. Little;Sarah Holte;Jean Pierre Routy;Eric S. Daar.
The New England Journal of Medicine (2002)
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
Pereyra F;Jia X;McLaren Pj.
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
Eric S. Daar;Xi Ling Li;Tarsem Moudgil;David D. Ho.
Proceedings of the National Academy of Sciences of the United States of America (1990)
Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
Grace A. McComsey;Douglas Kitch;Eric S. Daar;Camlin Tierney.
The Journal of Infectious Diseases (2011)
Reduced Antiretroviral Drug Susceptibility Among Patients With Primary HIV Infection
Susan J. Little;Eric S. Daar;Richard T. D'Aquila;Philip H. Keiser.
NATURALLY OCCURRING DOMINANT RESISTANCE MUTATIONS TO HEPATITIS C VIRUS PROTEASE AND POLYMERASE INHIBITORS IN TREATMENT-NAIVE PATIENTS
Thomas Kuntzen;Joerg Timm;Andrew Berical;Niall Lennon.
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Paul E. Sax;Camlin Tierney;Ann C. Collier;Margaret A. Fischl.
The New England Journal of Medicine (2009)
Diagnosis of Primary HIV-1 Infection
Eric S. Daar;Susan Little;Jacqui Pitt;Joanne Santangelo.
Annals of Internal Medicine (2001)
Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure
William A. O'Brien;Pamela M. Hartigan;Eric S. Daar;Michael S. Simberkoff.
Annals of Internal Medicine (1997)
Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
Eric S. Daar;Camlin Tierney;Margaret A. Fischl;Paul E. Sax.
Annals of Internal Medicine (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: